Welcome to our dedicated page for VVY news (Ticker: vvy), a resource for investors and traders seeking the latest updates and insights on VVY stock.
Vivoryon Therapeutics N.V. (VVY) is a clinical-stage biopharmaceutical company advancing novel therapies for kidney diseases and neurodegenerative disorders. This page aggregates official press releases and verified news about clinical trial progress, regulatory milestones, and strategic partnerships.
Investors and researchers will discover timely updates on therapeutic candidates, including detailed analyses of clinical endpoints like eGFR measurements in kidney studies. Content spans trial phase results, peer-reviewed research collaborations, and financial reporting.
Key categories include clinical development updates, regulatory communications, and scientific partnership announcements. All materials are sourced directly from the company or reputable financial/news outlets to ensure accuracy.
Bookmark this page for streamlined access to Vivoryon's latest developments, presented with context for both medical professionals and investment analysts. Check regularly for updates on pipeline advancements and data disclosures.
Vivoryon Therapeutics N.V. has secured a Standby Equity Purchase Agreement (SEPA) worth up to EUR 15 million with Yorkville Advisors Global, LP. The 36-month agreement allows Vivoryon to sell ordinary shares to Yorkville in individual tranches, with each tranche to 100% of the average daily trading volume over five days, up to 389,359 shares per tranche.
The shares will be issued at a 5% discount to market price, and the deal includes 167,028 shares as a commitment fee to Yorkville. Board members Erich Platzer and Frank Weber have agreed to lend 389,359 shares to Yorkville at no cost.
The funding will support Vivoryon's ongoing operations, preparations for a planned Phase 2b study in diabetic kidney disease for varoglutamstat, and advancement of preclinical studies for VY2149.
Vivoryon Therapeutics, a clinical stage company specializing in small molecule medicines development, has announced it will release its full year 2024 financial results and provide a corporate update on April 29, 2025.
The company will host a conference call and webcast at 3:00 pm CEST / 9:00 am EDT on the same day. The financial report will be accessible on Vivoryon's website, and participants can join the conference call through pre-registration on the provided link.
Vivoryon Therapeutics N.V. held a virtual R&D update highlighting key developments for their drug varoglutamstat. The event featured presentations from experts discussing the drug's beneficial effects on kidney function demonstrated in two independent Phase 2 studies. Key findings showed that varoglutamstat improved kidney function (eGFR) with statistical significance, with over 70% of patients responding to treatment.
The company plans to initiate a Phase 2b study in patients with type 2 diabetes and CKD stages 3b and worse. The drug's unique positioning stems from its oral availability, novel mechanism of action targeting inflammation and fibrosis through QPCTL inhibition, and demonstrated long-term safety. Notably, Vivoryon has decided to discontinue varoglutamstat's investigation in Alzheimer's disease to focus resources on kidney disease development.
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) has announced a virtual R&D update scheduled for February 18, 2025, at 3:00 pm CET / 9:00 am EST. The event will feature key presentations focusing on varoglutamstat's beneficial effects on kidney function and the company's clinical development plans for kidney disease treatments.
Two prominent Key Opinion Leaders (KOLs) will participate in the webcast: Dr. Tobias B. Huber, Chair of the Center of Internal Medicine at University Medical Center Hamburg-Eppendorf, serving as Medical Advisor for clinical study design, and Dr. Kevin Carroll, CEO of KJC Statistics, who will provide expertise on statistical analysis.
The session will include management presentations, discussions on varoglutamstat's market positioning, and an interactive Q&A segment for investors and analysts.
Vivoryon Therapeutics has announced significant developments in its kidney disease pipeline. A meta-analysis of VIVIAD and VIVA-MIND studies revealed that varoglutamstat treatment at 600mg twice daily significantly improved kidney function (eGFR) in the overall study population of 286 patients. The improvement became significant after 24 weeks and was maintained for up to 2 years.
The analysis showed a notably larger effect in patients with diabetes compared to those without. Of the total participants, 39 had diabetes (19 on varoglutamstat, 20 on placebo) while 247 were non-diabetic. The company has strengthened its patent portfolio with three new filings, including a composition of matter patent for varoglutamstat's active polymorph.
Vivoryon's key 2025 priority is advancing varoglutamstat in kidney disease through a planned Phase 2b study in diabetic kidney disease (DKD). Additionally, they've nominated a novel QPCT/L inhibitor candidate, VY2149, for development in inflammatory and fibrotic diseases.
Vivoryon Therapeutics reported Q3 2024 results and significant progress with varoglutamstat in kidney disease treatment. Two independent Phase 2 studies (VIVA-MIND and VIVIAD) demonstrated statistically significant improvement in kidney function. The VIVIAD study showed eGFR improvement of 3.4mL/min/1.73m2/year versus placebo, with even stronger results in diabetic patients (8.2mL/min/1.73m2/year).
The company plans to initiate a Phase 2 study in Diabetic Kidney Disease (DKD), pending additional funding or partnership. Financial results show R&D expenses increased to EUR 12.6 million, while G&A expenses decreased to EUR 4.9 million. Cash position stands at EUR 12.5 million as of September 30, 2024, with runway extended into Q3 2025.
Vivoryon Therapeutics announced topline Phase 2 data from the VIVA-MIND study of varoglutamstat in early Alzheimer's disease. The study showed a statistically significant improvement in kidney function, with patients treated with varoglutamstat 600mg BID showing an average improvement of >4mL/min/1.73m2 in estimated glomerular filtration rate (eGFR) versus placebo (p<0.001).
However, the study did not meet its primary and key secondary endpoints for Alzheimer's disease treatment, aligning with previous VIVIAD study results. The drug maintained a favorable safety profile with no new safety signals detected across over 400 participants in Phase 1 and 2 studies. The company plans to advance into a Phase 2 study in diabetic kidney disease, subject to additional funding/partnership.
Vivoryon Therapeutics, a clinical stage company focused on developing small molecule medicines for modulating pathologically altered proteins, has announced it will release its Q3 2024 financial results and provide a corporate update on December 10, 2024.
The company will host a conference call and webcast at 3:00 pm CET / 9:00 am ET. The event will be accessible via phone through pre-registration and through a live audio webcast on Vivoryon's website. Participants are advised to join 15 minutes before the scheduled start time.
Vivoryon Therapeutics presented Phase 2b results for varoglutamstat at ASN Kidney Week 2024, showing significant kidney function improvements. The study demonstrated a 3.4mL/min/year improvement in eGFR compared to placebo (p<0.0001), with an even more substantial 8.2mL/min/year improvement in diabetic patients (p=0.02). The drug showed excellent safety and tolerability with no increased proteinuria. Based on these results, Vivoryon is planning a new Phase 2 study focusing on patients with Diabetic Kidney Disease (DKD) stages 3b and 4. The company also sees potential applications in rare kidney diseases like Fabry disease and Alport syndrome.
Vivoryon Therapeutics (Euronext Amsterdam: VVY) announced that its abstract on Varoglutamstat has been selected for a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, California, from October 23 to 27. The abstract titled 'Varoglutamstat Increases Glomerular Filtration in Elderly Patients without Signs of Proteinuria and Potentially Offers a New Approach to Treat Diabetic Kidney Disease (DKD)' will be presented by Frank Weber, M.D., CEO, on October 25, 2024, at 5:40 PM PDT.
Varoglutamstat (PQ912) is a potent and selective inhibitor of human glutaminyl cyclases QPCT and QPCTL, with potential therapeutic applications in inflammatory and fibrotic diseases, neurodegenerative diseases, and cancer. Initially developed for Alzheimer's disease (AD), it has shown favorable safety and tolerability in various clinical studies. The Phase 2 VIVIAD study in AD included the investigation of kidney function to explore the role of QPCT/L inhibition on kidney function.
